What Ossiform does

Ossiform is a Danish MedTech company developing 3D printed bone substitutes made from beta-tricalcium phosphate (β-TCP), a resorbable bioceramic that remodels into native bone over time. Founded in 2017 and headquartered in Odense, Denmark, with a UK entity in London, the company operates an ISO 13485-certified clean room production facility. Ossiform serves two distinct customer bases: clinical (orthopedic, spine, maxillofacial, and extremity surgeons) and research (life science and biomedical researchers at academic and pharmaceutical institutions). Its clinical product, P3D Bone, is a patient-matched, structurally optimized bone graft substitute designed to address limitations of permanent implants (titanium, PEEK) and variable allografts, while the research line includes P3D Scaffolds (bone-mimicking 3D cell culture systems), Cell Culture Plates, and Ossi Ink (a printable bioink distributed through CELLINK).

The company's core technology is a proprietary 3D printing technique that gives shape and structure to β-TCP, enabling CAD/CAM-manufactured implants with tailored porosity, controlled resorption rates, and indication-specific biomechanical properties. The technology has been validated in preclinical studies only and is currently unapproved for clinical sale; FDA clearance for P3D Bone graft substitutes is anticipated within approximately 12 months of February 2025 (early 2026). The company holds a worldwide patent portfolio covering its bone printing technology.

Ossiform generates current revenue primarily from its research product line (P3D Scaffolds and Cell Culture Plates) sold direct via its website and from Ossi Ink distribution through CELLINK's global commercial channels. Clinical revenue from P3D Bone is not yet realized, pending regulatory clearance. The go-to-motion is hybrid: direct field sales for clinical accounts, inside sales and an online storefront for research customers, and channel partnerships (CELLINK globally, Imbros for Australia). The company is actively expanding into the U.S. market via the ABHI 2026 U.S. Accelerator Program and has set up clinical and medical affairs advisory functions to support its regulatory pathway.

Name

Ossiform

Legal name

Ossiform ApS

Website

https://ossiform.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Ossiform is a Danish MedTech company that 3D prints patient-matched, resorbable bone graft substitutes from beta-tricalcium phosphate (β-TCP). It serves orthopedic and maxillofacial surgeons with clinical implants (pre-FDA) and biomedical researchers with bone-mimicking cell culture scaffolds and bioinks.

Ownership category

akta.pro rank

Product category

Orthopedic Implants

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• 3D bone printing
• Resorbable bone implants
• Bioceramic bone substitutes
• Tissue engineering scaffolds
• Medical 3D bioprinting

Headquarters

HQ city

Odense

HQ country

Denmark

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Others, Marketing or Sales, Infrastructure

Revenue model

1. P3D Scaffolds (Research Products): Sale of P3D Scaffolds and cell culture products to research institutions worldwide for bone and cancer research, tissue engineering, and drug testing applications. Products are sold directly through Ossiform's website and via partners such as CELLINK.
2. Ossi Ink Bioink Distribution: Revenue from the co-exclusive distribution of Ossi Ink bioink through CELLINK's commercial channels. Sales began in 2024 under a strategic partnership with CELLINK.
3. P3D Bone Clinical Products (Pre-market): Future revenue anticipated from FDA-cleared P3D Bone graft substitutes for orthopedic and maxillofacial surgery. The company anticipates FDA clearance within approximately 12 months from February 2025. Clinical products are currently not approved for sale, pending regulatory clearance.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Ossiform develops and manufactures 3D printed bone substitutes and research scaffolds from beta-tricalcium phosphate (β-TCP), a resorbable bioceramic. Its clinical product line (P3D Bone / Ossiform Bone) targets orthopedic, spine, and maxillofacial surgeons with patient-matched bone graft substitutes that remodel into native bone. Its research product line (Ossiform Research Line) provides bioceramic 3D cell culture scaffolds (P3D Scaffolds) and compatible cell culture plates to academic and pharmaceutical researchers for bone tissue engineering, cancer modeling, and drug testing.

Product overview

Ossiform offers two distinct product lines: Ossiform Bone (clinical products) and Ossiform Research Line (research products). Ossiform Bone provides bio-integrative, structural bone graft substitutes made from 3D printed beta-tricalcium phosphate for orthopedic and spine applications. The Ossiform Research Line includes P3D Scaffolds (bioceramic bone-mimicking scaffolds for 3D cell culture), Cell Culture Plates (accessories for scaffold-based cultures), and the recently launched Ossi Ink bioink (in partnership with CELLINK). The company also offers downloadable protocols, technical data sheets, and research publications to support users of their research products.

Differentiator

Problem solved

Functional benefit

Brands

• P3D Scaffolds: Bioceramic 3D printed scaffolds made from β-tricalcium phosphate for bone and cancer research, providing bone-mimicking environments for in vitro studies with no batch-to-batch variance.
• P3D Bone
• Ossiform Bone
• Ossiform Research Line
• Ossi Ink

Products and services

• Ossiform Bone (P3D Bone) Patient-matched, bio-integrative, and structural orthopedic bone graft substitutes made from 3D printed beta-tricalcium phosphate. Designed for orthopedic, spine, maxillofacial, pelvis, and extremity reconstruction. Remodels into native vascularized bone, eliminating the need for permanent foreign body implantation. Currently pre-market, pending FDA clearance for first P3D Bone products.
• P3D Scaffolds Bioceramic 3D printed scaffolds made from pure beta-tricalcium phosphate that replicate the architecture and complexity of calcified bone tissue. Available in standard 96-, 24-, 12-, and 6-well plate sizes with grid or gyroid designs. No batch-to-batch variance; stable for long-term culture up to 16 months without material degradation; fully resorbable in vivo but stable in vitro. Used by academic and pharmaceutical researchers for bone tissue engineering, cancer/bone metastasis modeling, drug testing, and disease modeling.
• Cell Culture Plates Standard-sized cell culture plates compatible with P3D Scaffolds, available in 96-, 24-, 12-, and 6-well formats for various research applications.
• Ossi Ink A ready-to-print bioink based on Ossiform's P3D Bone material (beta-tricalcium phosphate), developed in partnership with CELLINK for bone-based research and bioprinting applications. Distributed co-exclusively through CELLINK's global commercial channels starting 2024.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Six partnerships are on record, tiered minor and core.

• Imbros Pty LtdminorChannel Partner/ Reseller/ Distributor · 1 June 2026Ossiform announced a new distribution partnership with Imbros Pty Ltd in June 2026, covering the Australian market. Imbros will distribute Ossiform's research products, expanding the company's reach into the Australian region.
• Association of British HealthTech Industries (ABHI)minorOthers · 1 January 2026Ossiform was selected for the ABHI 2026 U.S. Accelerator Program, a structured market preparation and support initiative for health technology companies entering the U.S. market. The program provides introductions to healthcare decision-makers, hospitals, health systems, and industry partners. Planned U.S. visits include Nashville, Memphis, Boston, New York, New Jersey, Philadelphia, Maryland, Washington D.C., and Texas (Houston, Austin, Dallas) throughout 2026.
• CELLINKcoreStrategic or Co-development Partner · 1 November 2023CELLINK and Ossiform entered a strategic partnership in November 2023 to commercialize Ossi Ink, a ready-to-print bioink based on Ossiform's P3D Bone β-TCP material. Sales began in 2024, distributed co-exclusively through CELLINK's global commercial channels. The partnership has scope for additional materials including clinical grade bioinks. CELLINK is a leading 3D bioprinting company with over 1,600 academic, pharmaceutical, and industrial laboratory customers.
• Finnadvance Ltd.coreTechnology or Integration · 1 April 2023Ossiform and Finnadvance announced a partnership in April 2023 to combine P3D Scaffolds with Finnadvance's AKITA Plate microfluidics platform. The integrated platform enables bone repair studies in a high-throughput compatible manner, with the AKITA system's flow increasing the signal-to-noise ratio up to 5 times. Finnadvance develops organ-on-chip platforms for physiologically relevant drug development.
• University of OxfordminorStrategic or Co-development Partner · 1 January 2023As part of Ossiform's P3D Scaffolds research grant program, researchers at the University of Oxford led by Jia-Ling Ruan received P3D Scaffolds to develop an in vitro bone metastasis model integrating FLASH radiotherapy studies on normal bone tissue and tumor tissue.
• University of Southern DenmarkminorStrategic or Co-development Partner · 1 January 2023As part of Ossiform's P3D Scaffolds research grant program, researchers at the University of Southern Denmark led by Professor Carsten Uhd Nielsen received P3D Scaffolds to study membrane transporter function in a dynamic in vivo-like 3D environment for pharmaceutical applications.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Zimmer Biomet: Orthopedic incumbent with bone graft substitute and biologics offerings. Represents established competition in the orthopedic reconstruction channels Ossiform targets with P3D Bone.
• DePuy Synthes (Johnson & Johnson): Orthopedic and neurosurgery division of J&J with a broad bone graft substitute portfolio. Represents the large incumbent competitive set in spine, extremity, and trauma bone reconstruction.
• Stryker: Global medical device incumbent with an extensive bone graft substitute portfolio (e.g., Vitoss, Bio4). Represents the entrenched competitive set Ossiform will face in orthopedic hospitals upon FDA clearance.
• Medtronic: Global medtech incumbent with bone graft substitutes and spine fusion biologics. Notable as Ossiform board member Jackie Fielding's prior employer, reflecting direct competitive overlap in spine and orthopedic adjacencies.

Direct peers

• Bioretec: Finnish medical device company specializing in bioresorbable bone implants and orthopedic fixation devices. Direct competitor in resorbable biomaterial bone substitutes for orthopedic applications.
• BellaSeno: Company developing resorbable polycaprolactone-based scaffolds for bone and cartilage regeneration using 3D printing. Comparable in patient-matched, resorbable scaffold approach to bone and musculoskeletal regeneration.
• Locate Bio: UK-based regenerative medicine company developing bone graft substitutes and tissue-engineered bone products. Comparable in clinical bone regeneration focus and UK/European regulatory pathway.
• Dimension Inx: U.S. company developing 3D-printed bone-healing and regenerative implants, including resorbable bone-substitute materials. Closely comparable in 3D-printed bone regeneration technology and target clinical applications.
• Particle3D: Danish-based company developing 3D-printed patient-specific bone implants from resorbable tricalcium phosphate materials. Direct peer in both technology (TCP-based 3D printing) and end market (orthopedic bone reconstruction).

Emerging players

• EpiBone: U.S. company developing living, patient-specific bone grafts using autologous stem cells and 3D scaffold technology. Emerging competitor in patient-matched bone regeneration with overlapping technology approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ossiform
• Xx.com/ossiform_com
• Facebookfacebook.com/Ossiform

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ossiform